(Billions of Yen)
| 2008 | 2009 | 2010 | 2011 | 2012 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Sales | 321.8 | 419.1 | 375.6 | 363.6 | 375.2 | ||||
| Excl.Tamiflu® | 313.4 | 342.9 | 357.4 | 354.9 | 363.2 | ||||
| Domestic | 279.9 | 309.3 | 324.4 | 315.3 | 320.9 | ||||
| Oncology field | 102.3 | 123.7 | 141.2 | 141.9 | 156.1 | ||||
| Avastin® | 20.1 | 34.9 | 52.6 | 56.4 | 65.5 | ||||
| Herceptin® | 23.7 | 29.7 | 25.3 | 25.9 | 28.7 | ||||
| Rituxan® | 20.5 | 21.1 | 23.0 | 22.9 | 24.7 | ||||
| Xeloda® | 4.8 | 6.6 | 10.7 | 10.0 | 10.9 | ||||
| Tarceva® | 4.5 | 5.8 | 7.9 | 8.3 | 9.5 | ||||
| Neutrogin® | 12.0 | 11.3 | 10.4 | 9.4 | 8.8 | ||||
| Femara® | 1.7 | 2.4 | 3.2 | 3.6 | 4.1 | ||||
| Kytril® | 10.9 | 8.6 | 5.5 | 3.4 | 2.4 | ||||
| Other products | 4.1 | 3.3 | 2.5 | 2.1 | 1.7 | ||||
| Bone and joint diseases field | 50.0 | 57.6 | 62.6 | 66.2 | 66.3 | ||||
| Actemra® | 3.4 | 8.4 | 14.1 | 17.5 | 17.1 | ||||
| Evista® | 16.5 | 17.9 | 18.7 | 18.5 | 16.1 | ||||
| Suvenyl® | 12.0 | 13.7 | 13.6 | 13.0 | 12.3 | ||||
| Alfarol® | 13.7 | 13.6 | 12.3 | 11.2 | 8.1 | ||||
| Edirol®** | - | - | - | 1.3 | 7.9 | ||||
| Other products | 4.5 | 3.9 | 4.0 | 4.6 | 4.7 | ||||
| Renal diseases field | 61.3 | 61.0 | 57.4 | 50.7 | 48.1 | ||||
| Mircera®** | - | - | - | 5.9 | 17.8 | ||||
| Epogin® | 44.9 | 44.4 | 40.0 | 28.8 | 14.5 | ||||
| Oxarol® | 10.0 | 10.6 | 12.0 | 12.2 | 12.3 | ||||
| Renagel® | 5.7 | 5.3 | 4.9 | 3.1 | 3.1 | ||||
| Other products | 0.7 | 0.7 | 0.5 | 0.7 | 0.4 | ||||
| Transplant, Immunology & Infectious diseases field | 24.0 | 26.2 | 25.8 | 22.8 | 20.3 | ||||
| Pegasys® | 9.7 | 11.1 | 10.5 | 8.3 | 6.9 | ||||
| Copegus® | 4.2 | 4.9 | 4.5 | 3.3 | 2.0 | ||||
| CellCept® | 4.0 | 4.4 | 5.2 | 5.7 | 6.5 | ||||
| Other products | 6.1 | 5.8 | 5.7 | 5.5 | 4.9 | ||||
| Other Fields | 42.3 | 40.9 | 37.4 | 33.8 | 30.1 | ||||
| Sigmart® | 15.0 | 14.7 | 13.0 | 11.1 | 9.5 | ||||
| Other products | 27.3 | 26.3 | 24.4 | 22.6 | 20.5 | ||||
| Overseas | 33.5 | 33.6 | 33.0 | 39.6 | 42.3 | ||||
| Actemra® | 3.8 | 8.9 | 12.7 | 20.5 | 25.6 | ||||
| Neutrogin® | 25.9 | 21.3 | 17.0 | 15.6 | 13.9 | ||||
| Sigmart® | 2.0 | 1.9 | 2.2 | 2.1 | 1.4 | ||||
| Other products | 1.7 | 1.5 | 1.2 | 1.4 | 1.4 | ||||
| Tamiflu® | 8.4 | 76.2 | 18.2 | 8.7 | 12.0 | ||||
| Ordinary sales | 7.1 | 36.2 | 1.6 | 5.4 | 10.2 | ||||
| Govt. stockpile etc. | 1.3 | 40.0 | 16.6 | 3.3 | 1.9 | ||||
| Other operating revenues | 5.1 | 9.8 | 3.9 | 9.9 | 16.0 | ||||
| Revenues (total) | 326.9 | 428.9 | 379.5 | 373.5 | 391.2 | ||||
| Domestic | 293.1 | 392.6 | 342.9 | 327.9 | 341.3 | ||||
| Overseas | 33.8 | 36.4 | 36.6 | 45.6 | 49.9 | ||||
*Excluding OTC sales
**Edirol (launched in April 2011), Mircera (launched in July 2011)
Oncology Field
- Neutrogin® (Billions of Yen)
- Herceptin® (Billions of Yen)
- Rituxan® (Billions of Yen)
- Avastin® (Billions of Yen)
- Kytril® (Billions of Yen)
Bone and Joint Diseases Field
- Alfarol® (Billions of Yen)
- Actemra® (Billions of Yen)
- Edirol® (Billions of Yen)
Renal Diseases Field
- Mircera® (Billions of Yen)
- Epogin® (Billions of Yen)
- Oxarol® (Billions of Yen)
Transplant, Immunology & Infectious Diseases Field
- Tamiflu® (Billions of Yen)
- Pegasys®/Copegus® (Billions of Yen)
Other Fields
- Sigmart® (Billions of Yen)
Sales by Strategic Field (FY2012)
Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.
Variance and % are calculated based on amounts shown.
